XNCR - ゼンコア (Xencor Inc.) ゼンコア

 XNCRのチャート


 XNCRの企業情報

symbol XNCR
会社名 Xencor Inc (ゼンコア)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ゼンコア(Xencor Inc.)は臨床段階のバイオ医薬品会社である。同社は重篤で生命を脅かす疾病を治療するためにモノクローナル抗体の発見・開発に焦点を当てる。同社は2つのフェーズⅡ試験で自己免疫疾患のために開発されるXmAb5871と、フェーズⅠ試験で喘息のために開発されるXmAb7195の2種類の臨床段階の製品候補を開発する。また、ヘテロ二量体Fc二重特異性技術を用いた二重特異性抗体候補のパイプライン、急性骨髄性白血病(AML)の治療の第I相試験であるXmAb14045、B細胞悪性腫瘍の治療のための第I相試験であるXmAb13676、神経内分泌腫瘍の治療のために前臨床開発中のXmAb18087、および様々な癌の治療のために前臨床開発中であり、その二重チェックポイント阻害剤であるXmAb20717が含まれる。   ゼンコアは、米国のバイオ医薬品会社。癌や自己免疫性炎症疾患の治療のための抗体やタンパク質を開発する。異常細胞を特異的に狙う同社のタンパク質設計の自動化技術の活用により、抗体を開発している。また、他社との提携による臨床抗体プログラムも行う。本社は、カリフォルニア州モンロビア。   Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.
本社所在地 111 West Lemon Avenue Monrovia CA 91016 USA
代表者氏名 Bassil I. Dahiyat Bassil I. Dahiyat
代表者役職名 President Chief Executive Officer Founder Director
電話番号 +1 626-305-5900
設立年月日 35643
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数
url www.xencor.com
nasdaq_url https://www.nasdaq.com/symbol/xncr
adr_tso
EBITDA EBITDA(百万ドル) -86.59400
終値(lastsale) 35.33
時価総額(marketcap) 1972336536.96
時価総額 時価総額(百万ドル) 1898.088
売上高 売上高(百万ドル) 18.03000
企業価値(EV) 企業価値(EV)(百万ドル) 1642.68
当期純利益 当期純利益(百万ドル) -58.90800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Xencor Inc revenues decreased from $16M to $0K. Net loss increased from $23.2M to $55.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development - Balancing val increase of 54% to $43.4M (expense) Stock-based Compensation in R&D increase of 62% to $6M (expense).

 XNCRのテクニカル分析


 XNCRのニュース

   Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2021 Results - Earnings Call Transcript  2021/08/05 04:10:47 Seeking Alpha
   Xencor EPS beats by $1.48, beats on revenue  2021/08/04 20:38:43 Seeking Alpha
   Xencor Reports Second Quarter 2021 Financial Results  2021/08/04 20:01:00 Business Wire
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. Xencor is applying its leading protein engineering tools and XmAb technology to overcome historical challenges in creating therapeutic mol
   Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021  2021/07/28 20:01:00 Business Wire
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a cor
   INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution  2021/06/14 20:01:00 Intrado Digital Media
Purchase of Xencor Option potentially eliminates approximately 2.1 mill ion shares of INmune future common stock dilution upon execution.
   INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution  2021/06/14 20:01:00 Intrado Digital Media
Purchase of Xencor Option potentially eliminates approximately 2.1 mill ion shares of INmune future common stock dilution upon execution.
   MorphoSys AG Consensus Indicates Potential 79.7% Upside  2021/06/04 12:44:07 DirectorsTalk
MorphoSys AG with ticker code (MOR) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 41 and 28 with a mean TP of 34.5. With the stocks previous close at 19.2 this is indicating there is a potential upside of 79.7%. There is a 50 day moving average of 21.94 while the 200 day moving average is 25.44. The market cap for the company is $2,568m. Find out more information at: /> [stock_market_widget type="chart" symbol="MOR" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn''s disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer''s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis.
   MorphoSys AG Consensus Indicates Potential 37.4% Upside  2021/05/28 08:08:26 DirectorsTalk
MorphoSys AG with ticker code (MOR) have now 3 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 40.89 and 21.93 with the average target price sitting at 30.25. Now with the previous closing price of 22.02 this would indicate that there is a potential upside of 37.4%. There is a 50 day moving average of 22.08 and the 200 day MA is 25.58. The market capitalisation for the company is $2,847m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="MOR" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn''s disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer''s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis.
   Xencor and Vir to benefit from for FDA authorization for COVID-19 therapy: SVB Leerink  2021/05/27 15:11:41 Seeking Alpha
   Analysts Opinions Are Mixed on These Healthcare Stocks: Cooper Co (COO), AbbVie (ABBV) and Xencor (XNCR)  2021/05/27 08:05:49 Smarter Analyst
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cooper Co (COO), AbbVie (ABBV) and The post Analysts Opinions Are Mixed on These Healthcare Stocks: Cooper Co (COO), AbbVie (ABBV) and Xencor (XNCR) appeared first on Smarter Analyst .
   The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split  2021/04/15 11:49:24 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ: TXG ) Affimed N.V. (NASDAQ: AFMD ) Bio-Techne Corporation (NASDAQ: TECH ) - announced out-licensing of antibody treatment candidate to Xencor, Inc. (NASDAQ: XNCR ) BioNTech SE (NASDAQ: BNTX ) - reacted to increased EU orders for its COVID-19 vaccine in the wake of the Johnson & Johnson (NYSE: JNJ ) setback Globus Medical, Inc. (NYSE: GMED ) Medpace Holdings, Inc. (NASDAQ: MEDP ) Medtronic plc (NYSE: MDT ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natus Medical Incorporated (NASDAQ: NTUS ) NuVasive, Inc. (NASDAQ: NUVA ) PLx Pharma Inc. (NASDAQ: PLXP ) PPD, Inc. (NASDAQ: PPD ) - moved on rumors of a potential buyout by Thermo Fisher Scientific Inc. (NYSE: TMO ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 14) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Celyad Oncology SA (NASDAQ: CYAD ) Design Therapeutics, Inc. (NASDAQ: DSGN ) Kronos Bio, Inc. (NASDAQ: KRON ) Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT ) Metacrine, Inc. (NASDAQ: MTCR ) Millendo Therapeutics, Inc. (NASDAQ: MLND ) Nabriva Therapeutics plc (NASDAQ: NBRV ) Osmotica Pharmaceuticals plc (NASDAQ: OSMT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Stocks In Focus Regenxbio Doses First Patient In Gene Therapy Study REGENXBIO Inc. (Nasdaq: RGNX ) said it dosed the first patient in Cohort 3 of the ongoing Phase I/2 trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II, also known as Hunter Syndrome, in patients up to five years old.
   Mizuho Securities Stick to Their Buy Rating for Xencor Inc By Investing.com  2021/04/12 02:55:01 Investing.com
Mizuho Securities Stick to Their Buy Rating for Xencor Inc
   Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates - Stocks News Feed  2021/02/25 12:15:42 Stocks News Feed
Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor’s modular suite of XmAb technology platforms. Xencor’s XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures. Xencor and its pharmaceutical partners are now advancing 20 clinical-stage XmAb-engineered drug candidates to treat various life-threatening… Read More »Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates
   Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics - Stocks News Feed  2021/02/25 10:01:00 Stocks News Feed
— Collaboration joins together Xencor’s modular XmAb engineered protein platforms with UCLA’s expertise in biology to rapidly create and advance potential new medicines — Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technology Development Group (UCLA TDG) today announced an… Read More »Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゼンコア XNCR Xencor Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)